Organization · Venture Capital
i&i Biotech Fund
i&i Biotech Fund is a venture capital firm based in Luxembourg, focusing on early-stage investments in biotechnology and life sciences startups, particularly academic spin-offs from Central and Eastern Europe.
Overview
What i&i Biotech Fund does
What i&i Biotech Fund is
i&i Biotech Fund is a venture capital firm based in Luxembourg, focusing on early-stage investments in biotechnology and life sciences startups, particularly academic spin-offs from Central and Eastern Europe.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2021
- Approximate age
- About 5 years
- Structured capabilities
- Funder
- Last reviewed
- April 22, 2026
Official channels
Find i&i Biotech Fund elsewhere
Open the official website or a supported primary organization account.
Capability profile
i&i Biotech Fund as a funder
Investment thesis
i&i Biotech Fund focuses exclusively on life science ventures, investing in innovative European companies addressing unmet medical needs through strong scientific foundations.
Focus narrative
The fund invests in early-stage startups within the life sciences sector, specifically targeting drug discovery, medtech, diagnostics, and AI verticals. i&i Biotech Fund typically provides initial investments starting at €150,000, with a primary investment range between €0.5 million and €2 million. While its primary focus is on Central and Eastern Europe, the fund is open to collaborating with teams from across Europe.
Value beyond capital
i&i Biotech Fund adds value to its portfolio companies by leveraging its strong connections within the life sciences ecosystem, providing strategic guidance, and facilitating access to resources and expertise from affiliated institutions such as the Institute of Organic Chemistry and Biochemistry.
Terms and economics
- Typical check
- $150,000–$2,000,000
- Sweet spot
- $1,000,000
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 20
Portfolio context
Notable portfolio companies include: Dracen Pharmaceuticals (2021) - Drug discovery; Celeris Therapeutics (2022) - Drug discovery, AI; Sampling Human (2022) - Diagnostics; CasInvent (2022) - Drug discovery; Nanoligent (2022) - Drug discovery; Enzyre (2022) - Diagnostics; Sophomer (2022) - Medtech; Delta Life Science (2023) - Diagnostics; HeartBeat.bio (2023) - Medtech; Captain T Cell (2023) - Drug discovery; LAM-X (2024) - Medtech; Antiverse (2024) - Drug discovery, AI; Vasa Therapeutics (2024) - Drug discovery; Ternary Therapeutics (2024) - Drug discovery, AI; iQure (2024) - Drug discovery; KyDo Therapeutics (2025) - Drug discovery; T-CURX (2025) - Drug discovery.
Common questions
What to know about i&i Biotech Fund
Upseed classifies i&i Biotech Fund under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 22, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.